Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study

B. Kirkham[1], P. Nash[2], D. Reina[3], S. Navarra[4], E. Quebe-Fehling[5], C. Gaillez[5], C. Sastre[6], P.J. Mease[7]

[1]Guys Hospital and St Thomas NHS Trust, London, UK; [2]Griffith University, Brisbane, Australia; [3]Hospital de Sant Joan Despí Moisès Broggi, Spain; [4]Section of Rheumatology, University of Santo Tomas Hospital, Manila, Philippines; [5]Novartis Pharma AG, Basel, Switzerland; [6]Novartis Farmaceutica SA, Barcelona, Spain; [7]Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA.

Supplementary Figure 1. Resolution of baseline dactylitis up to Week 104 in anti-TNF naïve patients



Patients with resolution of dactylitis at baseline to Week 104 is presented based on Kaplan-Meïer estimates. Percentages of patients with resolution at Week 16, 52 and 104 were derived as 1 minus the survival function at Days 112, 365, and 729, respectively.

LD, loading dose; N, total number of patients with dactylitis at baseline; n, number of responders; NL, without loading dose;

SEC, secukinumab; TNF, tumor necrosis factor

Supplementary Figure 2. mNAPSI and DLQI outcomes in patients with dactylitis at baseline through Week 104



Data presented as observed.

DLQI, Dermatology Life Quality Index; LD, with loading dose; mNAPSI, modified Nail Psoriasis Severity Index; N, total number of randomized patients; NL, without loading dose; SEC, secukinumab

Supplementary Table 1. Radiographic progression in patients with or without dactylitis at baseline through Week 104

	With Dactylitis at Baseline			Without Dactylitis at Baseline		
Mean (SD)	**SEC 300 mg LD (N=82)**	**SEC 150 mg LD (N=80)**	**SEC 150 mg NL (N=103)**	**SEC 300 mg LD (N=140)**	**SEC 150 mg LD (N=140)**	**SEC 150 mg NL (N=119)**
n	77	72	89	131	132	106
52 weeks	0.1 (2.0)	0.1 (2.5)	0.2 (0.9)	0.0 (0.9)	0.2 (1.2)	0.3 (1.5)
n	70	64	76	121	117	93
104 weeks	0.8 (6.6)*	0.9 (4.1)	0.2 (1.2)	0.1 (1.5)	0.3 (1.2)	0.5 (2.7)

Analysis is based on the patients with evaluable X-rays at both baseline and at Weeks 24, 52 or 104. At each time point, only patients with a value at both baseline and that time point are included. Baseline is defined as the last observation on the day of or before the first dose of study drug, or the first observation within 30 days post dosing when no observation available prior to dosing. Week 24 missing radiographic values and values for placebo patients rescued at Week 16 were imputed via linear extrapolation. *Included is one outlier patient with a very high mTSS change of 53. Mean changes from baseline in vdH-mTSS (≤0.5 change from baseline).

LD, with loading dose; N, total number of patients randomized; NL, without loading dose; SEC, secukinumab; vdH-mTSS, van der Heijde-modified total Sharp score.